Skip to main content
RAPP
NASDAQ Life Sciences

Rapport 获得 2000 万美元前期付款，最高可达 3.08 亿美元里程碑奖励在中国 RAP-219 合作伙伴关系

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$30.24
Mkt Cap
$1.441B
52W Low
$7.4
52W High
$42.269
Market data snapshot near publication time

summarizeSummary

Rapport Therapeutics 已经宣布与 Tenacia Biotechnology 建立战略合作伙伴关系，以开发和商业化其关键药物候选物 RAP-219 在大中华地区。根据条款，Rapport 将获得 2000 万美元的前期付款，并有资格获得最高 3.08 亿美元的潜在开发和商业里程碑奖励，以及根据净销售额的分层版税。这一合作伙伴关系提供了重大非稀释资本，增强了 Rapport 的财务状况，并允许继续投资于其他项目。关键是，它利用 Tenacia 的区域专业知识来加速 RAP-219 的全球 3 期开发，用于局灶性发作性癫痫，并在中国设有临床试验站点。这笔交易扩大了 RAP-219 的市场覆盖范围，并降低了其开发途径的风险，代表了公司长期前景的一个重大积极因素。

在该公告发布时，RAPP的交易价格为$30.24，交易所为NASDAQ，所属行业为Life Sciences，市值约为$14.4亿。 52周交易区间为$7.40至$42.27。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed RAPP - Latest Insights

RAPP
Apr 21, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
8
RAP-219 Shows Sustained Efficacy in Focal Onset Seizure Trial, Advancing to Phase 3
Sentiment: Positive
View Wiseek Article
RAPP
Apr 21, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
RAP-219 Shows Sustained Seizure Reduction, Improved Half-Life in Phase 2a Follow-up for Focal Onset Seizures
Sentiment: Positive
View Wiseek Article
RAPP
Apr 17, 2026, 4:37 PM EDT
Filing Type: 144
Importance Score:
7
Officer Files Intent to Sell Nearly $800K in Rapport Therapeutics Stock
Sentiment: Negative
View Wiseek Article
RAPP
Apr 17, 2026, 4:25 PM EDT
Filing Type: 144
Importance Score:
7
10% Shareholder Third Rock Ventures Files Intent to Sell Over $17M in Rapport Therapeutics Stock
Sentiment: Negative
View Wiseek Article
RAPP
Apr 13, 2026, 4:37 PM EDT
Filing Type: 144
Importance Score:
7
Officer Files Intent to Sell $661K in Rapport Therapeutics Shares, Continuing Recent Selling Pattern
Sentiment: Negative
View Wiseek Article
RAPP
Mar 10, 2026, 8:16 AM EDT
Filing Type: S-3ASR
Importance Score:
8
Rapport Therapeutics Files New $150M At-The-Market Offering to Fund Clinical Development
Sentiment: Neutral
View Wiseek Article
RAPP
Mar 10, 2026, 7:25 AM EDT
Filing Type: 10-K
Importance Score:
9
Rapport Therapeutics Advances Lead Candidate RAP-219 to Phase 3 with FDA Support, Secures Major China Partnership
Sentiment: Positive
View Wiseek Article
RAPP
Mar 10, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
9
Rapport Therapeutics Reports Strong Phase 2a FOS Data, Accelerates Phase 3, and Secures Strategic China Partnership
Sentiment: Positive
View Wiseek Article
RAPP
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Rapport Secures $20M Upfront, Up to $308M Milestones in China RAP-219 Partnership
Sentiment: Positive
View Wiseek Article
RAPP
Jan 07, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Rapport Therapeutics Establishes $110M At-The-Market Equity Offering Program
Sentiment: Negative
View Wiseek Article